MedTrace Logo

Pharmacokinetic Drug-Drug Interaction Study of Rucaparib

NCT02740712 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2023-06-09

No results posted yet for this study

Summary

The purpose of this study is to assess pharmacokinetic concentrations of multiple probes alone followed by assessment of the same drug pharmacokinetic concentrations when the patient has steady-state exposure to rucaparib followed by cycle-by-cycle treatment with rucaparib continuing until disease progression or other reason for discontinuation.

Conditions

  • Neoplasms

Interventions

DRUG

Caffeine

200 mg (4 x 50mg) Tablet

DRUG

Warfarin

10 mg (2 x 5mg) Tablet

DRUG

Omeprazole

40 mg Tablet

DRUG

Midazolam

5 mg/mL

DRUG

digoxin

.25 mg Tablet

DRUG

Vitamin K

10 mg Tablet

DRUG

Rucaparib

200 \& 300 mg tablet

Sponsors & Collaborators

  • pharmaand GmbH

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-03-31
Completion
2019-09-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02740712 on ClinicalTrials.gov